Roche & Pathai Expand Digital Pathology for Diagnostics

Roche announced that it has signed an agreement with PathAI, a world leader in artificial intelligence (AI)-based pathology technologies.Under the terms of this Agreement, PathAI will collaborate with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in companion diagnostics. As the only third-party algorithm development company for AI-driven analytics, RTD will work with PathAI for a predetermined period while retaining the ability to develop its algorithm for peer-to-peer analytics further. PathAI maintains the ability to freely develop algorithms beyond peer analysis.

"As the market leader in complementary diagnostics, we are committed to bringing innovation to personalized medicine," said Jill German, director of Roche Tissue Diagnostics. "This collaboration with PathAI will allow us to accelerate our ability to meet the needs of biomedical companies looking to develop AI-enabled diagnostics and provide the end-to-end solution to finding the right solutions."The algorithms developed under this Agreement are delivered using Roche's immunological solutions.

"This collaboration with Roche demonstrates our commitment to advancing the fields of digital pathology and AI-enabled analytics for drug development and clinical care," said PathAI CEO and founder Dr. Andy Beck said: "High-value diagnostic products integrated into laboratory workflows will accelerate the transition to digital pathology as the standard to support clinicians in diagnosis and prognosis."

Under a previous agreement in October 2021, the two companies jointly developed an image analysis workflow for pathologists. This workflow integrates PathAI's image analysis transformations into Roche's Navify Digital Pathology software platform. The PathAI algorithm has been fully integrated into Roche's open environment for the first time.

In collaboration with Roche and other leading pharmaceutical companies, we will identify and develop innovative predictive analytics to target patients most likely to respond to specific treatments. As a global partner in diagnostics, we help advance precision medicine by providing diagnostic confidence through a portfolio of high-value medicines that help doctors determine the right treatment faster. Our leadership and expertise in digital pathology, including AI-based image analysis algorithms, drive the development of digital pathology solutions and diagnostics, helping to scale up very important treatments for patients.